Organization | Department of Health and Human Services

Department of Health and Human Services Report issue

Government Phase 1 Phase 2 Phase 3 Phase 4

Founded: Washington, D.C. United States (1953)

Organization Overview

First Clinical Trial

2003

NCT00410865

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Agency for Healthcare Research and Quality (AHRQ) | BARDA (Biomedical Advanced Research and Development Authority) | Barda (Contract No HHSO100201300011C) | Biomedical Advanced Research and Development Authority | Biomedical Advanced Research and Development Authority (BARDA) (RoW) | Department of Health and Human Services | U.S. Administration on Community Living | US Department of Health and Human Services

Active Ingredients

Drugs in Phase 4 Trials (15)

cefazolin (ancef) (1 trial)

iodophor (1 trial)

lithium (lithonate) (1 trial)

live attenuated influenza virus vaccine (Flumist) (2 trials)

metformin (glucophage) (1 trial)

nicotine (nicorette) (2 trials)

oseltamivir (tamiflu) (1 trial)

peramivir (rapivab) (4 trials)

povidone-iodine (betadine) (1 trial)

quetiapine (seroquel) (1 trial)

retapamulin (altabax) (1 trial)

tecovirimat (tpoxx) (3 trials)

warfarin (coumadin) (2 trials)

Drugs in Phase 3 Trials (36)

abatacept (orencia) (1 trial)

albuterol (proventil) (1 trial)

anthrax vaccine, adsorbed (Biothrax) (7 trials)

avibactam (Avycaz) (1 trial)

aztreonam (azactam) (1 trial)

carbavance (3 trials)

cefepime (maxipeme) (1 trial)

ceftobiprole (2 trials)

cenicriviroc (1 trial)

colistin (2 trials)

daptomycin (cubicin) (1 trial)

inactivated influenza vaccine (17 trials)

infliximab (remicade) (1 trial)

influenza vaccine, recombinant hemagglutinin (1 trial)

levofloxacin (levaquin) (1 trial)

matrix m1 (2 trials)

meropenem (merrem) (4 trials)

metronidazole (flagyl) (2 trials)

mrna-1273 (Spikevax) (3 trials)

mva-bn (JYNNEOS) (1 trial)

nitroglycerin (transderm-nitro) (1 trial)

piperacillin (pipracil) (1 trial)

plazomicin (Zemdri) (3 trials)

reltecimod (1 trial)

remdesivir (Veklury) (1 trial)

ridinilazole (1 trial)

rvsvdelta-zebov-gp (1 trial)

sars-cov-2 rs (1 trial)

sodium chloride (6 trials)

solithromycin (3 trials)

taniborbactam (1 trial)

tazobactam (Zosyn) (1 trial)

tigecycline (tygacil) (1 trial)

tranexamic acid (cyklokapron) (1 trial)

vancomycin (Vancocin) (3 trials)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 2 Trials (31)

ah5n6c (1 trial)

aluminum hydroxide (Gaviscon) (1 trial)

as03 (2 trials)

biotinylated red blood cells (1 trial)

cad3-marburg vaccine (1 trial)

cad3-zebov (1 trial)

ciprofloxacin (cipro) (3 trials)

clt-008 (1 trial)

desflurane (suprane) (2 trials)

doxycycline (vibramycin) (2 trials)

epoetin (Epogen) (1 trial)

gepotidacin (2 trials)

gsk2798745 (2 trials)

h5 vaccine antigen (1 trial)

influenza g1 mha (1 trial)

influenza vlp vaccine (4 trials)

interleukin-12 (2 trials)

inv-102 (2 trials)

laninamivir octanoate hydrate (3 trials)

mf59 (2 trials)

mrna-1325 (1 trial)

myeloid progenitor cells (2 trials)

panblok (1 trial)

platelets (3 trials)

sargramostim (leukine) (2 trials)

simvastatin (zocor) (1 trial)

tivantinib (2 trials)

topiramate (topamax) (1 trial)

vax2012q (1 trial)

vis410 (1 trial)

vxa-a1.1 (1 trial)

Drugs in Phase 1 Trials (57)

3m-052-af (1 trial)

426c.mod.core-c4b (1 trial)

90-yttrium (1 trial)

adc6-hivgp140 (1 trial)

adc7-hivgp140 (1 trial)

aluminum (1 trial)

anthrax immune globulin (Anthrasil) (1 trial)

atoltivimab (Inmazeb) (1 trial)

atropine (1 trial)

BG505 MD39.3 gp151 CD4KO mRNA (1 trial)

bg505 md39.3 gp151 mrna (1 trial)

bg505 md39.3 mrna (1 trial)

botulinum antitoxin heptavalent (a b c d e f g) - (equine) (1 trial)

botulism antitoxin bivalent (equine) types a and b (1 trial)

botulism antitoxin heptavalent (a, b, c, d, e, f, g) - (equine) (BAT) (1 trial)

bpsc-1001 vaccine (1 trial)

ceftibuten (cedax) (2 trials)

ch505tf gp120 (1 trial)

clindamycin (cleocin) (1 trial)

eravacycline (Xerava) (1 trial)

fluconazole (diflucan) (1 trial)

FP8v1-rTTHC (1 trial)

gla-se (1 trial)

il-12 dna (1 trial)

ingn 201 (advexin) (1 trial)

isoamyl nitrite (1 trial)

lipoplysaccharide (1 trial)

mdx-1303 (Valortim) (3 trials)

mgd014 (1 trial)

mgd020 (1 trial)

moxifloxacin (avelox) (2 trials)

mrna-1893 (1 trial)

n332-gt5 gp140 (1 trial)

nasoshield (1 trial)

parathyroid hormone (Natpara) (1 trial)

pgdm1400 (1 trial)

pgt121 (1 trial)

phosphate (1 trial)

plg0206 (1 trial)

px563l (1 trial)

qingre liangkou ningxin fang (1 trial)

qpx2014 (2 trials)

qpx2015 (1 trial)

qpx7728 (2 trials)

qpx7831 (3 trials)

qpx9003 (1 trial)

rpa563 (1 trial)

sab-185 (2 trials)

sd-np-gt8 (1 trial)

snipr001 (1 trial)

terconazole (terazol) (1 trial)

trimer 4571 (2 trials)

trimer 6931 (1 trial)

trl1068 (1 trial)

vaborbactam (Vabomere) (1 trial)

vrc07-523ls (1 trial)

Drugs in Other Trials (11)

bisphenol a (1 trial)

chlorhexidine (hibitane) (2 trials)

donepezil (aricept) (1 trial)

enoxaparin (lovenox) (1 trial)

fiber (1 trial)

galantamine (reminyl) (1 trial)

loperamide (imodium) (1 trial)

mupirocin (bactroban) (2 trials)

polyethylene glycol (1 trial)

rivastigmine (exelon) (1 trial)

vitis vinifera (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Radiation Syndrome (Phase 2)

Alcoholic Intoxication (Phase 2)

Alcoholism (Phase 2)

Anemia (Phase 2)

Anemia, Aplastic (Phase 2)

Anemia, Neonatal (Phase 2)

Anemia, Sickle Cell (Phase 2)

Anthrax (Phase 3)

Asthma (Phase 3)

Bacteremia (Phase 3)

Bacterial Infections (Phase 2)

Bipolar Disorder (Phase 4)

Blood Coagulation Disorders (Phase 4)

Botulism (Phase 1)

Carcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Clostridium Infections (Phase 2)

Colitis (Phase 2)

Communicable Diseases (Phase 4)

Coronavirus Infections (Phase 3)

Cough (Phase 2)

Cystitis (Phase 2)

Diarrhea (Phase 4)

Disease (Phase 4)

Fasciitis (Phase 3)

Fasciitis, Necrotizing (Phase 3)

Fatigue (Phase 3)

Fournier Gangrene (Phase 3)

Gangrene (Phase 3)

Headache (Phase 3)

Heart Failure (Phase 3)

Hematologic Diseases (Phase 1)

Hematologic Neoplasms (Phase 2)

Hemorrhage (Phase 1)

Hemorrhagic Fever, Ebola (Phase 3)

Hemorrhagic Fevers, Viral (Phase 3)

Hemostatic Disorders (Phase 4)

Infections (Phase 4)

Influenza, Human (Phase 4)

Influenza in Birds (Phase 3)

Intraabdominal Infections (Phase 3)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma (Phase 1)

Mouth Neoplasms (Phase 1)

Multiple Myeloma (Phase 1)

Myalgia (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasms, Plasma Cell (Phase 1)

Nervous System Diseases (Phase 3)

Neutropenia (Phase 2)

Osteoporosis (Phase 1)

Osteoporosis, Postmenopausal (Phase 1)

Paralysis (Phase 1)

Pharyngitis (Phase 3)

Pneumonia (Phase 3)

Pneumonia, Bacterial (Phase 3)

Pneumonia, Ventilator-Associated (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Preleukemia (Phase 2)

Pyelonephritis (Phase 3)

Radiation Injuries (Phase 2)

Renal Insufficiency (Phase 1)

Severe Acute Respiratory Syndrome (Phase 3)

Skin Diseases, Bacterial (Phase 3)

Smallpox (Phase 4)

Soft Tissue Infections (Phase 3)

Spinal Cord Injuries (Phase 3)

Staphylococcal Infections (Phase 4)

Syndrome (Phase 2)

Thrombocytopenia (Phase 2)

Urinary Tract Infections (Phase 3)

Vaginitis (Phase 1)

Wounds and Injuries (Phase 3)

Zika Virus Infection (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 150
# of Trial APIs: 150